NanoString Technologies has announced a collaboration with Oregon Health & Science University (OHSU) for the development of novel GeoMx Digital Spatial Profiler (DSP) protein assays to profile breast cancer.
These assays will be designed to enhance breast cancer tumour analysis and may inform clinical decision-making of patient treatment options. The work will be performed under the GeoMx Translational Leadership Network (GTLN), and the newly formed GeoMx Clinical Consortium, with the goal of developing clinical applications on the GeoMx DSP platform.
Under the collaboration, pathologists at OHSU intend to design a new GeoMx protein assay with up to 30 targets, including existing breast cancer diagnostic markers and novel biomarker candidates. The GeoMx protein assays will be analytically and clinically validated by OHSU for potential use as laboratory-developed tests. The development of a high-content spatial protein test using GeoMx may present new opportunities to enhance pathology insights for improved patient outcomes.
“We believe that the GeoMx DSP is the only spatial platform with the potential to serve the needs of discovery research, translational research, and clinical diagnostics. OHSU is a great partner to advance the platform towards the clinical environment and we look forward to collaborating with these thought leaders,” said Brad Gray (President & CEO, NanoString).
“The development of novel GeoMx DSP protein assays expands the potential applications of spatial biology with the goal of providing better patient care through advanced molecular testing,” said Dr Christopher Corless (Executive Director, Knight Diagnostic Laboratories, OHSU Knight Cancer Institute). “The GeoMx DSP platform is uniquely suited for this work based on the high-plex and automated capabilities of the system for use with formalin-fixed paraffin-embedded samples.”
https://www.nanostring.com/products/geomx-digital-spatial-profiler/geomx-dsp
